Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222592
Title: Decreased brain serotonin in rbfox1 mutant zebrafish and partial reversion of behavioural alterations by the SSRI fluoxetine
Author: Adel, Maja R.
Antón Galindo, Ester
Gago-Garcia, Edurne
Arias-Dimas, Ángela
Arenas Solà, Concepción
Artuch, Rafael
Cormand Rifà, Bru
Fernàndez Castillo, Noèlia
Keywords: Serotonina
Malalties mentals
Genètica
Serotonin
Mental illness
Genetics
Issue Date: 16-Feb-2024
Publisher: MDPI
Abstract: RBFOX1 functions as a master regulator of thousands of genes, exerting a pleiotropic effect on numerous neurodevelopmental and psychiatric disorders. A potential mechanism by which RBFOX1 may impact these disorders is through its modulation of serotonergic neurotransmission, a common target for pharmacological intervention in psychiatric conditions linked to RBFOX1. However, the precise effects of RBFOX1 on the serotonergic system remain largely unexplored. Here we show that homozygous rbfox1sa15940 zebrafish, which express a shorter, aberrant rbfox1 mRNA, have significantly reduced serotonin levels in telencephalon and diencephalon. We observed that the acute administration of fluoxetine partially reverses the associated behavioural alterations. The hyperactive phenotype and altered shoaling behaviour of the rbfox1sa15940/sa15940 zebrafish could be reversed with acute fluoxetine exposure in the Open Field and the Shoaling test, respectively. However, in the other paradigms, hyperactivity was not diminished, suggesting a distinct intrinsic motivation for locomotion in the different paradigms. Acute fluoxetine exposure did not reverse the alterations observed in the aggression and social novelty tests, suggesting the involvement of other neurological mechanisms in these behaviours. These findings underscore the importance of investigating the intricate working mechanisms of RBFOX1 in neurodevelopmental and psychiatric disorders to gain a better understanding of the associated disorders along with their pharmacological treatment.
Note: Reproducció del document publicat a: https://doi.org/10.3390/ph17020254
It is part of: Pharmaceuticals, 2024, vol. 17, num.2
URI: https://hdl.handle.net/2445/222592
Related resource: https://doi.org/10.3390/ph17020254
ISSN: 1424-8247
Appears in Collections:Articles publicats en revistes (Genètica, Microbiologia i Estadística)

Files in This Item:
File Description SizeFormat 
839481.pdf3.3 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons